of the Phase 2 WILLOW study (NCT05162586). Results will be presented at the 16thInternational Congress on Systemic Lupus Erythematosus (LUPUS 2025), taking place May 21-24 in Toronto.

WILLOW is a global, multicenter, randomized, placebo-controlled Phase 2 study evaluating three doses of enpatoran taken twice daily (25 mg, 50 mg and 100 mg) versus placebo plus standard of care (SoC) over 24 weeks. The study features a unique design across two lupus cohorts, including both patients with active SLE and CLE. Cohort A focused on patients with CLE or SLE with active lupus rash and evaluated organ-specific disease activity using the Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score, a well-defined endpoint in CLE studies that measures different aspects of mucocutaneous manifestations. Cohort B was designed to evaluate the effect of enpatoran on systemic disease activity of SLE patients with the BICLA response endpoint.

Cohort A met its
=*=*=*=*=*=
当前为第2/10页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页